BPC-157: an unfinished prescription dossier

The BPC-157 peptide

BPC-157 is a synthetic chain of 15 amino acids, copied from part of a protein found in human gastric juice. Its unusually stubborn survival in that fluid gave it the description stable gastric pentadecapeptide. The stomach was the starting point; the literature has since followed it into tendons, blood vessels, bowel repairs and the brain.

I distrust the tidy story that a molecule's birthplace tells us where it will work. The stomach origin is interesting, certainly. The experiments are more interesting, because they sometimes resist the story that the name invites.

The ulcer experiment

In a 2004 study of gastric ulcers in rats, BPC-157 reduced ulcer area and accelerated healing. Researchers used 400 ng/kg and 800 ng/kg; the ulcer-formation inhibition ratio at higher doses was 45.7–65.6%. The stomach lining and repair tissue rebuilt sooner.

Here is the awkward detail: delivery into muscle outperformed delivery into the stomach. I expected the gastric origin to make the stomach route the obvious winner. That experiment spoiled the neatness of the idea. That route comparison has soured my confidence in capsule claims built solely on survival in gastric juice.

The ulcer, gastritis and fistula dossier follows those questions through the gut literature. Every repair result there belongs to an animal experiment; controlled human gut efficacy remains unestablished.

Three human reports

The 2025 musculoskeletal review describes only three small human pilot studies. They concern knee pain, bladder symptoms in twelve people and intravenous safety in two healthy adults. Their questions, routes and measurements differ. Adding them together would produce a misleading impression of one clinical programme.

I credit a report for the question it actually asks. The intravenous pilot's unchanged safety blood tests deserve to be recorded, and the absence of large controlled trials deserves equal space. An animal repair result and a person's symptom report still leave a substantial clinical question between them. The human reports and safety concerns are collected separately from the animal research.

The prescription question

FDA has not approved a finished BPC-157 drug. A prescribing decision, a pharmacy's authority to use a bulk ingredient and FDA approval each have their own requirements. BPC-157 appears in FDA's table of nominations withdrawn from review, separate from the active Category 2 table. FDA's safety concerns remain on record. The legal-status dossier explains that record and the separate rules for compounding.

The study amounts matter because a number becomes slippery when its species, unit or route falls away. A number stripped of its study context gets no easy pass from me.